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Abstract
RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma (SLL). Patients aged ≥65 years (n= 269) were randomized 1:1 to once-daily ibrutinib 420 mg
continuously or chlorambucil 0.5–0.8 mg/kg for ≤12 cycles. With a median (range) follow-up of 60 months (0.1–66),
progression-free survival (PFS) and overall survival (OS) benefits for ibrutinib versus chlorambucil were sustained (PFS
estimates at 5 years: 70% vs 12%; HR [95% CI]: 0.146 [0.098–0.218]; OS estimates at 5 years: 83% vs 68%; HR [95% CI]:
0.450 [0.266–0.761]). Ibrutinib benefit was also consistent in patients with high prognostic risk (TP53 mutation, 11q
deletion, and/or unmutated IGHV) (PFS: HR [95% CI]: 0.083 [0.047–0.145]; OS: HR [95% CI]: 0.366 [0.181–0.736]).
Investigator-assessed overall response rate was 92% with ibrutinib (complete response, 30%; 11% at primary analysis).
Common grade ≥3 adverse events (AEs) included neutropenia (13%), pneumonia (12%), hypertension (8%), anemia (7%),
and hyponatremia (6%); occurrence of most events as well as discontinuations due to AEs decreased over time. Fifty-eight
percent of patients continue to receive ibrutinib. Single-agent ibrutinib demonstrated sustained PFS and OS benefit versus
chlorambucil and increased depth of response over time.
Introduction
Chronic lymphocytic leukemia (CLL) predominantly
affects older individuals who frequently have comorbidities
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that may preclude the use of intensive chemoimmunother-
apy regimens, such as fludarabine, cyclophosphamide, and
rituximab (FCR) [1–3]. Before establishment of the
chlorambucil-based CD20 combinations, single-agent
chlorambucil was considered a standard of care in older
patients with CLL [4, 5].
Ibrutinib is a first-in-class, oral, once-daily inhibitor of
Bruton’s tyrosine kinase (BTK), which as a single agent has
led to prolonged progression-free survival (PFS) and overall
survival (OS) in patients with previously treated CLL [6, 7].
RESONATE-2 is an international phase 3 study evaluating
the efficacy and safety of first-line ibrutinib compared with
chlorambucil in older patients with CLL or small lympho-
cytic lymphoma (SLL) [8]. The primary analysis (median
follow-up of 18.4 months) demonstrated an 84% reduction
in the risk of disease progression (PD) or death (as assessed
by an independent review committee) and significant
improvement in OS for ibrutinib compared with chlor-
ambucil, supporting the initial approval of first-line ibrutinib
for CLL/SLL in the United States and for CLL in the
European Union, with ibrutinib now approved for CLL in
over 90 countries [8–10]. Data previously reported from this
study after a median follow-up of 28.5 months demon-
strated a sustained PFS benefit for ibrutinib and improved
depth of response over time, with no new unexpected safety
concerns [11]. Continued long-term study follow-up is
important to provide quantitative assessments of response
durability, dimensions of patients’ well-being, and safety
with continuous single-agent ibrutinib treatment to inform
clinical practice.
Herein, we present the efficacy and safety outcomes for
first-line ibrutinib treatment after a median follow-up of
5 years from the RESONATE-2 study. This represents the
longest follow-up to date from a phase 3 trial of BTK-
directed therapy in the first-line setting for CLL.
Subjects and methods
Study design and population
RESONATE-2 collectively includes the phase 3, open-
label, international, randomized study PCYC-1115 and
extension study (PCYC-1116) comparing the efficacy and
safety of ibrutinib versus chlorambucil in first-line CLL/
SLL. Detailed methods have been previously reported [8].
Briefly, previously untreated patients without chromosome
17p deletion [del(17p)] aged ≥65 years with CLL/SLL
requiring therapy per published criteria [12] were rando-
mized in a 1:1 ratio to oral ibrutinib (420 mg once daily)
until PD or unacceptable toxicity, or 12 cycles of chlor-
ambucil (0.5 mg/kg, increased up to 0.8 mg/kg as tolerated,
on days 1 and 15 of each 28-day cycle). Following
confirmation of PD, patients randomized to chlorambucil
were eligible to cross over to second-line treatment with
ibrutinib.
This study was conducted according to principles of the
Declaration of Helsinki and the International Conference on
Harmonisation Guidelines for Good Clinical Practice and
was approved by the institutional review boards of partici-
pating institutions. All patients provided written informed
consent. This study was registered with ClinicalTrials.gov,
numbers NCT01722487 and NCT01724346.
Endpoints and assessments
Endpoints included PFS, OS, overall response rate (ORR),
improvement in hematologic parameters, patient-reported
outcomes, and safety. Long-term PD and response were
assessed by the investigator per 2008 International Work-
shop on CLL (iwCLL) criteria [12]. Long-term safety data
are reported for patients who were initially randomized to
ibrutinib. Nonhematologic adverse events (AEs) were gra-
ded using Common Terminology Criteria for Adverse
Events, v4.03 [13]. Hematologic AEs were graded using
iwCLL criteria [12].
Statistical analysis
PFS and OS were analyzed according to the Kaplan–Meier
method. To adjust for the impact of crossover on OS, sen-
sitivity analyses were performed as previously described
[14].
Data sharing statement
Requests for access to individual participant data from
clinical studies conducted by Pharmacyclics LLC, an
AbbVie Company, can be submitted through Yale Open
Data Access Project site at http://yoda.yale.edu.
Results
Patients
A total of 269 patients were randomized to ibrutinib (n=
136) or chlorambucil (n= 133; Supplementary Fig. 1). As
previously reported, baseline characteristics were well
balanced across treatment arms (Table 1) [8]. Treatment
with first-line ibrutinib was ongoing in 79 (58%) patients
after a median follow-up of 60 months (range,
0.1–66 months), while 56 (41%) discontinued treatment
(Table 2). Of 133 patients randomized to chlorambucil, 96
experienced PD (75 crossed over to ibrutinib and 21 did not
cross over after PD), one crossed over to receive ibrutinib
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without documented PD, and 36 patients remained on the
chlorambucil arm without PD. Of 21 patients who did not
cross over after PD (cross over to ibrutinib was not man-
datory), six died, six were still on study without crossing
over, and six discontinued the study. Of the 36 patients
remaining on the chlorambucil arm without PD, 16 were
still on study, 11 discontinued the study, and nine died.
Progression-free survival and overall survival
Ibrutinib significantly prolonged PFS compared with
chlorambucil (median not reached vs 15.0 months [95%
confidence interval (CI): 10.2–19.4]), with an 85% reduc-
tion in the risk of PD or death (hazard ratio, 0.146 [95% CI:
0.098–0.218]; Fig. 1). At 5 years, 70% of patients treated
with ibrutinib and 12% with chlorambucil were estimated to
be progression-free and alive. Eight (6%) of 136 patients
discontinued ibrutinib due to PD.
A PFS benefit for ibrutinib over chlorambucil was
observed across all patient subgroups examined, including
those with the high-risk prognostic features of TP53
mutation, chromosome 11q deletion (del[11q]), and/or
unmutated immunoglobulin heavy chain variable region
(IGHV) (PFS: HR 0.083 [95% CI: 0.047–0.145]) (Fig. 2).
When examined individually, the presence of del(11q) and
unmutated IGHV were each also associated with increased
PFS in ibrutinib-treated patients compared with
chlorambucil-treated patients. Ibrutinib dramatically
reduced the risk of PD or death by 97% compared with
chlorambucil in patients with del(11q) (Fig. 3a). Ibrutinib
reduced the risk of PD or death by 90% and 85% compared
with chlorambucil for patients with either unmutated and
mutated IGHV, respectively (Fig. 3b). PFS was not sig-
nificantly different for ibrutinib-treated patients with
unmutated and mutated IGHV. In patients treated with
ibrutinib, 79% of patients with del(11q) and 67% of patients
with unmutated IGHV were estimated alive and
progression-free at 5 years. Though patients with del(17p)
CLL were excluded from the study, 12 ibrutinib-treated
patients had TP53 mutation; median PFS was not reached
for ibrutinib-treated patients with TP53 mutation or TP53
wild type (HR [95% CI: 0.866 [0.264–2.846]) and the
5-year estimates were 56% and 73%, respectively. Only
three patients randomized to chlorambucil had TP53
mutation so no comparison could be made between
treatments.
Median OS was not reached for either the ibrutinib or
chlorambucil arms (HR [95% CI], 0.450 [0.266–0.761]).
OS estimates at 5 years were 83% for ibrutinib and 68% for
chlorambucil without censoring for crossover from chlor-
ambucil to ibrutinib and were 80% for chlorambucil after
censoring for crossover to ibrutinib treatment after PD
(Supplementary Table 1). In patients with high prognostic
risk CLL (TP53 mutation, del[11q], and/or unmutated
IGHV), OS at 5 years without censoring for crossover to
ibrutinib was 84% for ibrutinib and 62% for chlorambucil
(HR 0.376 [95% CI: 0.180–0.786]).
Table 2 Duration of treatment with first-line ibrutinib
Ibrutinib
n= 136
Median (range) duration of ibrutinib treatment,
monthsa
57.1 (0.7–66.0)
Treatment duration, n (%)
>3 years 99 (73)
>4 years 88 (65)
>5 years 37 (27)
Continuing ibrutinib on study, n (%) 79 (58)
Continuing on commercial ibrutinib, n (%) 0 (0)
Discontinued ibrutinib, n (%) 56 (41)
Adverse event 29 (21)
Progressive disease 8 (6)
Death 8 (6)
Withdrawal by patient 7 (5)
Investigator decision 4 (3)
aOne patient did not receive any doses of ibrutinib
Table 1 Baseline characteristics
Ibrutinib
n= 136
Chlorambucil
n= 133
Median age (range), years 73 (65–89) 72 (65–90)
≥70 years, n (%) 96 (71) 93 (70)
Male, n (%) 88 (65) 81 (61)
ECOG performance status, n (%)
0 60 (44) 54 (41)
1–2 76 (56) 79 (59)
Rai stage III or IV, n (%) 60 (44) 62 (47)
CIRS score >6, n (%) 42 (31) 44 (33)
Creatinine clearance <60 mL/min,
n (%)
60 (44) 67 (50)
Bulky disease ≥5 cm, n (%) 54 (40) 40 (30)
β2-microglobulin >3.5 mg/L, n (%) 85 (63) 89 (67)
Hemoglobin ≤11 g/dL, n (%) 51 (38) 55 (41)
Platelet count ≤100 × 109/L, n (%) 35 (26) 28 (21)
del(11q), n/N (%) 29/130 (22) 25/121 (21)
Unmutated IGHV, n/N (%) 58/101 (57) 60/103 (58)
TP53 mutation n/N (%) 12/124 (10) 3/94 (3)
High prognostic risk features,a n (%) 74 (54) 69 (52)
CIRS Cumulative Illness Rating Scale, ECOG Eastern Cooperative
Oncology Group, IGHV immunoglobulin heavy chain variable region
aTP53 mutation, del(11q), and/or unmutated IGHV
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Fig. 1 Progression-free survival
with single-agent ibrutinib
versus chlorambucil in first-line
treatment for CLL/SLL.
Survival analyses are from
randomization until event or
censored at last evidence of non-
PD; vertical tick marks indicate
censored patients. CI confidence
interval, CLL chronic
lymphocytic leukemia, NE not
estimable, PD progressive
disease, SLL small lymphocytic
lymphoma
Fig. 2 Progression-free survival according to baseline factor subgroups
of interest. CI confidence interval, del(11q) chromosome 11q deletion,
ECOG Eastern Cooperative Oncology Group, HR hazard ratio, IGHV
immunoglobulin heavy chain variable region
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Overall response
With a median follow-up of 5 years (up to 66 months), the
ORR including partial response with lymphocytosis was
92% for patients treated with ibrutinib compared with 37%
for patients treated with chlorambucil. The proportion of
patients with a best response of CR or CR with incomplete
marrow recovery (CRi) increased over time (Fig. 4). In the
ibrutinib arm, investigator-assessed CR/CRi rates increased
from 11% at the primary analysis (median follow-up,
Fig. 3 Progression-free survival by a del(11q) status and b IGHV
mutational status. Survival analyses are from randomization until event
or censored at last follow-up; vertical tick marks indicate censored
patients. CI confidence interval, del(11q) chromosome 11q deletion,
IGHV immunoglobulin heavy chain variable region, NE not estimable,
NR not reached, PFS progression-free survival
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18 months) to 30% after a median follow-up of 5 years. In
the ibrutinib arm, ORR and CR rates for patients with high-
risk features (i.e., del[11q] or unmutated IGHV) were
consistent with the rates seen for all patients treated with
ibrutinib.
Sustained hematologic improvement
Among patients with baseline cytopenias treated with
ibrutinib, the proportion of patients with sustained hema-
tologic improvement increased over time. Significantly
more ibrutinib-treated patients with baseline anemia
(hemoglobin ≤11 g/dL) had sustained improvement in
hemoglobin levels compared with chlorambucil (90%
[46 of 51] vs 45% [25 of 55]; P < 0.0001). Similarly, sig-
nificantly more patients with baseline thrombocytopenia
(platelets ≤100 × 109/L) had sustained improvement in pla-
telet counts after ibrutinib treatment compared with chlor-
ambucil (89% [31 of 35] vs 46% [13 of 28]; P= 0.0007).
For patients treated with ibrutinib, median hemoglobin level
was 11.6 g/dL at treatment initiation, 13.2 g/dL at year 1,
and 13.7 g/dL at year 5 (Fig. 5). Median platelet counts for
patients treated with ibrutinib were 143 × 109/L at treatment
initiation, 155 × 109/L at year 1, and 147 × 109/L at year 5
(Fig. 5).
Patient-reported outcomes and disease-related
symptoms
Patient-reported outcomes as assessed with the EQ-5D-5L
and FACIT-F were improved with ibrutinib versus chlor-
ambucil. Clinically meaningful improvement in the EQ-5D-
5L UIS (≥0.084) [15] and in EQ-5D-5L VAS were observed
significantly more frequently with ibrutinib than with
chlorambucil (60% vs 44% of patients, P= 0.0089; 65% vs
52%, P= 0.0329, respectively), though no significant
difference between ibrutinib- and chlorambucil-treated
patients was observed for the proportion of patients who
had clinically meaningful improvement in FACIT-F (63%
vs 53%). By repeated measure analysis, ibrutinib resulted in
significantly greater score improvements over time in EQ-
5D-5L UIS (P= 0.0079), EQ-5D-5L VAS (P= 0.0003),
and FACIT-F (P= 0.0018) (Supplementary Fig. 2). There
were no differences in EQ-5D-5L UIS, EQ-5D-5L VAS, or
FACIT-F after chlorambucil-treated patients crossed over to
ibrutinib following PD compared with before chlorambucil-
treated patients crossed over (Supplementary Fig. 3).
Consistent with patient-reported outcomes, when com-
pared with chlorambucil, ibrutinib resulted in higher rates of
improvements in disease-related symptoms of weight loss,
fatigue, fever, night sweats, anorexia, and abdominal dis-
comfort due to splenomegaly (Supplementary Fig. 4).
Safety
At data cutoff, the median duration of ibrutinib treatment
was 57 months (range, 0.7–66 months) (Table 2) and
median relative dose intensity was 98%. The most frequent
AEs of any grade with ibrutinib were diarrhea (50%), cough
(36%), and fatigue (36%) (Table 3), and the prevalence of
many AEs decreased with time on treatment.
Among AEs of particular interest, including those iden-
tified during early ibrutinib clinical development, hyper-
tension of any grade occurred in 35 (26%) patients,
including 13%, 6%, 6%, 5%, and 7% of patients in years
0–1, 1–2, 2–3, 3–4, and 4–5, respectively (Supplementary
Fig. 5). Grade 3 hypertension occurred in 12 (9%) patients,
with no grade 4 or 5 events. Atrial fibrillation of any grade
occurred at any time in 22 (16%) patients, including 6%,
1%, 6%, 3%, and 4% of patients in years 0–1, 1–2, 2–3,
3–4, and 4–5, respectively (Supplementary Fig. 5). Grade 3
atrial fibrillation occurred in 7 (5%) patients, with no grade
Fig. 4 Overall response rate per
investigator assessment with
first-line ibrutinib. Cumulative
best response over time in all
patients. Percentages of patients
in each category of response
may not total the overall
proportion with a response
because of rounding. CR
complete response, CRi
complete response with
incomplete marrow recovery,
nPR nodular partial response,
ORR overall response rate, PR
partial response, PR-L partial
response with lymphocytosis,
SD stable disease
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4 or 5 events. Major hemorrhage (grouped terms) events
occurred in 15 (11%) patients, including 4%, 3%, 1%, 3%,
and 2% of patients in years 0–1, 1–2, 2–3, 3–4, and 4–5,
respectively (Supplementary Fig. 5). Grade 3 major
hemorrhage occurred in 8 (6%) patients, grade 4 in 1 (1%)
patient, and no grade 5 events occurred. Of the patients who
experienced grade ≥3 major hemorrhage, 6 (67%) were
taking concomitant anticoagulation therapy.
Treatment discontinuations decreased over time on
ibrutinib, with 7% of patients discontinuing because of AEs
in years 0–1, 6% in years 1–2, 5% in years 2–3, 6% in years
3–4, and 1% in years 4–5 (Supplementary Fig. 6). Thirty-
eight patients experienced AEs leading to discontinuation of
ibrutinib; those reported in ≥2 patients were atrial fibrillation
(n= 4), and palpitations, pneumonia, and worsening CLL
(n= 2 each), in addition to 2 deaths with unknown cause.
The rates of dose reductions due to AEs were similar
over time (Supplementary Fig. 6), with rates of 9% for
patients in years 0–1, 8% in years 1–2, 6% in years 2–3, 5%
in years 3–4, and 7% in years 4–5. Dose reductions due to
any-grade AEs occurred in 27 patients; 25 (93%) had
improvement or resolution of the AE following dose
reduction. At the time of data cutoff, 12/27 remained on
ibrutinib and 15/27 had discontinued ibrutinib at any time
during follow-up after the dose reduction. Reasons for
subsequent discontinuation at any time during follow-up
were for any AE (n= 9; two patients had dose reduction
and then discontinued because of the same AE), withdrawal
from the study (n= 3), PD (n= 2), and physician decision
(n= 1). AEs leading to dose reduction reported in >1
patient were thrombocytopenia (n= 3), and anemia,
arthralgia, diarrhea, fatigue, and palpitations (n= 2 each).
After AE-related dose reductions, ibrutinib dose was suc-
cessfully re-escalated back to previous dose for ≥2 treatment
cycles in six (22%) patients, and re-escalated treatment
lasted a median of 589 days (preceding dose reductions
lasting a median of 103 days).
Ibrutinib dosing was held for ≥7 consecutive days
because of any grade AEs in 70 patients and 60 patients had
complete resolution of the AE following dose hold. At the
time of data cutoff, 36/70 of these patients remained on
ibrutinib and 34/70 had discontinued ibrutinib at any time
during follow-up after the dose hold. Reasons for sub-
sequent discontinuation at any time during follow-up
included any further AE (n= 20), withdrawal from
study (n= 6), PD (n= 5), death (n= 2), or physician
decision (n= 1). Of note, only six patients discontinued due
to the same AE after the dose hold (atrial fibrillation, cer-
ebral hemorrhage, cognitive disorder, myelodysplastic
syndrome, non–small cell lung cancer, and staphylococcal
sepsis). For these 70 patients, the median duration between
first dose hold of ibrutinib to study treatment discontinua-
tion or last known date alive for those still on treatment was
48 months (maximum 64+ months). Following dose hold,
ibrutinib was restarted at the same dose in 42 patients and at
a reduced dose in 22 patients.
At the time of data cutoff, 23 patients randomized to
ibrutinib died (8 while on treatment); 4 due to PD (all were
aged ≥70 years). One AE of pneumonia was considered
possibly related to ibrutinib. There were six patients for
Fig. 5 Hemoglobin levels and platelet counts over time in ibrutinib-treated patients. The horizontal line represents the lower limit of normal for
platelet counts. CI confidence interval
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whom cause of death was unknown, and of the remaining,
there were two infections, three second malignancies, and
one each reported as multiorgan failure, heart attack, sudden
death, heart failure, sepsis, pulmonary fibrosis, and septic
shock (Supplementary Fig. 7).
Outcomes following ibrutinib discontinuation
Outcomes following discontinuation of first-line ibrutinib
treatment are shown in Supplementary Table 2. Median OS
following discontinuation was not reached (range, 0–64+
months) in patients who discontinued ibrutinib because of
AEs (n= 29). Only eight patients discontinued ibrutinib
because of PD (including two patients due to Richter’s
transformation); of these patients, 50% are still alive or had
exited study with no known death at the data cut. The
median OS following ibrutinib discontinuation due to PD
was 20 months (range, 1+ to 28 months). Median PFS for
patients who were in CR/CRi at ibrutinib discontinuation
was 56 months (95% CI: 44, NE) compared with 33 months
(95% CI: 26, 46) for patients who were not CR/CRi at
ibrutinib discontinuation (HR [95% CI]: 0.390 [0.118,
1.285]).
Of patients with available follow-up data after ibrutinib
discontinuation, 14 patients received subsequent therapy for
CLL, including standard chemoimmunotherapy (FCR,
BR, or GC) (n= 8), chemotherapy (n= 3), and novel
agents (n= 3). Of nine patients with best overall response to
subsequent therapy reported, seven responded, one had
stable disease, and one had PD. Eleven of the 14 patients
remained alive at last follow-up, two patients withdrew
consent, and one patient died.
Discussion
With long-term follow-up of the RESONATE-2 study,
single-agent ibrutinib continues to demonstrate significant
Table 3 Most frequent adverse
events over time in patients
treated with first-line ibrutinib
Adverse events, n (%) Ibrutinib
n= 135a
0–1 year
n= 135
1–2 years
n= 123
2–3 years
n= 111
3–4 years
n= 100
4–5 years
n= 89
Totald,e
n= 135
Any gradeb 133 (99) 118 (96) 104 (94) 97 (97) 87 (98) 135 (100)
Diarrhea 57 (42) 11 (9) 13 (12) 8 (8) 8 (9) 67 (50)
Fatigue 38 (28) 27 (22) 21 (19) 19 (19) 18 (20) 48 (36)
Cough 26 (19) 13 (11) 12 (11) 10 (10) 11 (12) 49 (36)
Peripheral edema 23 (17) 17 (14) 13 (12) 12 (12) 11 (12) 37 (27)
Anemia 22 (16) 12 (10) 9 (8) 9 (9) 6 (7) 35 (26)
Nausea 27 (20) 9 (7) 5 (5) 3 (3) 3 (3) 35 (26)
Pyrexia 20 (15) 8 (7) 7 (6) 6 (6) 6 (7) 36 (27)
Arthralgia 19 (14) 13 (11) 10 (9) 6 (6) 13 (15) 35 (26)
Upper respiratory tract infection 17 (13) 8 (7) 10 (9) 10 (10) 7 (8) 35 (26)
Hypertension 16 (12) 12 (10) 15 (14) 16 (16) 17 (19) 31 (23)
Constipation 16 (12) 14 (11) 11 (10) 6 (6) 7 (8) 28 (21)
Vomiting 16 (12) 5 (4) 7 (6) 3 (3) 1 (1) 27 (20)
Grade ≥3c 78 (58) 48 (39) 30 (27) 39 (39) 32 (36) 112 (83)
Neutropenia 11 (8) 4 (3) 1 (1) 1 (1) 0 (0) 17 (13)
Pneumonia 7 (5) 3 (2) 3 (3) 4 (4) 2 (2) 16 (12)
Hypertension 6 (4) 2 (2) 0 3 (3) 4 (4) 11 (8)
Anemia 8 (6) 1 (1) 1 (1) 0 0 (0) 10 (7)
Hyponatremia 3 (2) 4 (3) 0 0 1 (1) 8 (6)
Atrial fibrillation 2 (1) 0 4 (4) 1 (1) 0 (0) 7 (5)
Cataract 1 (1) 1 (1) 1 (1) 1 (1) 3 (3) 7 (5)
Diarrhea 5 (4) 0 1 (1) 0 0 (0) 6 (4)
aOne patient did not receive any doses of ibrutinib
bOccurring in ≥20% of patients
cOccurring in ≥4% of patients
dMedian 5 years follow-up
eIncludes 5–6 year data
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and durable clinical benefit in older patients, including those
with high-risk prognostic features (TP53 mutation,
del(11q), and/or unmutated IGHV). No new safety signals
emerged over the extended treatment duration, and many
events decreased over time. This is the longest follow-up
report of patients receiving first-line treatment with a BTK
inhibitor in a phase 3 study to date.
With up to 66 months of follow-up, the median
investigator-assessed PFS per iwCLL criteria was not
reached in the ibrutinib arm and was 15 months (95% CI
[10–19]) in the chlorambucil arm. The rate of PD during
ibrutinib treatment was low; only 8/136 (6%) patients pro-
gressed while receiving ibrutinib, implying a low rate of
developing the BCR pathway mutations associated with
PD. Improvement in PFS with first-line ibrutinib compared
with chlorambucil remains durable, as evidenced by an 85%
reduction in the risk of progression or death. Accordingly,
when comparing similar timepoints between studies, the 3-
year PFS rate with ibrutinib (82%) was higher than that with
chlorambucil (25%) and appears higher than rates pre-
viously reported for first-line chemoimmunotherapy with
FCR (70%) or BR (55%) in an older patient population than
in the CLL10 study, although the proportion of patients
with unmutated IGHV was higher in CLL10 than in the
current study [16, 17]. Three-year PFS rates for ibrutinib
also appeared favorable compared with chlorambucil in
combination with obinutuzumab (<40%) in older, less fit
patients in the CLL11 study [5].
In addition, ibrutinib substantially improved PFS in high-
risk patients with del(11q) or unmutated IGHV compared
with chlorambucil. Whereas the presence of del(11q) [18]
or unmutated IGHV [16, 19] confers poor outcomes in the
chemoimmunotherapy setting, we observed prolonged PFS
with ibrutinib compared with chlorambucil in patients with
del(11q) or with unmutated IGHV. Patients with the com-
posite high prognostic risk genomics of del(11q), unmutated
IGHV, or TP53 mutation experienced markedly improved
PFS with ibrutinib, with a 92% reduction in risk of PD or
death versus chlorambucil. However, there were no mean-
ingful differences in PFS for ibrutinib-treated patients when
these high-risk factors were evaluated individually
(del[11q], unmutated IGHV, or TP53 mutation). The
exclusion of patients with del(17p) is an important limita-
tion of this analysis given its prognostic significance and
frequent overlap with TP53 mutations [20]. Taken together,
our results suggest that these high-risk prognostic features
may not have meaningful prognostic value with ibrutinib-
mediated inhibition of the BCR pathway, unlike with
chemoimmunotherapy.
Cross-study analyses suggest that the clinical benefit is
highest when ibrutinib is used as initial therapy versus as a
later line of therapy [7], and the present study demonstrates
the durability of those outcomes in the first-line setting with
more than 5 years follow-up. Real-world studies of patients
receiving first-line treatment, including patients who would
have been excluded from RESONATE-2 due to age <65
years or the presence of del(17p), demonstrate similar
response rates (71–82% vs 92%) and proportion of dis-
continuations due to AEs (51–63% vs 52% of patients who
discontinued) as the present study [21–24].
Additional randomized trials have found that adding
rituximab to ibrutinib does not increase PFS compared with
single-agent ibrutinib in the first-line setting [25] and in
relapsed/refractory patients or high-risk patients with
del(17p) or TP53 mutations receiving first-line treatment
[26]. In the iLLUMINATE study of ibrutinib plus obinu-
tuzumab, median PFS was also not reached for patients with
del(11q) nor for patients with unmutated IGHV, similar to
what we report here for single-agent ibrutinib (Fig. 3).
These results with del(11q) and IGHV mutational status are
also consistent across two other phase 3 studies of ibrutinib
in different patient populations and as a single agent or in
combination regimens [6, 18, 27]. A pooled analysis of
three phase 3 randomized studies (RESONATE, RESO-
NATE-2, and HELIOS) further showed that the prognostic
risk factors of del(11q) and unmutated IGHV traditionally
associated with worse outcomes in patients with CLL have
less prognostic significance with ibrutinib therapy in
patients without del(17p) [28].
Our results also demonstrate an improved depth of
response over time with first-line ibrutinib. Investigator-
assessed CR/CRi rates in ibrutinib-treated patients
improved from 11% at the primary analysis (median follow-
up 18.4 months) [8] to 30% after a median of 5 years
follow-up. In addition, we continue to observe sustained
improvement in anemia and thrombocytopenia with ibruti-
nib, which are important and frequent reasons patients with
CLL initiate treatment. These improvements may help
alleviate the fatigue that is a major component of symptom
burden and reduced quality of life in patients with CLL
[29], especially those with advanced age and multiple
comorbidities [29]. Given that patients with CLL may
remain on ibrutinib for many years, durable improvement in
quality of life during treatment is an important goal. In this
study, ibrutinib treatment improved patient-reported out-
comes and disease-related symptoms that were sustained
through extended follow-up, in contrast to the worsened
quality of life outcomes reported by patients treated with
chlorambucil, as PD occurred earlier and more frequently.
As the majority of patients with CLL (including those in
this study) are elderly and may be less tolerant of toxicities,
treatments with a tolerable safety profile in long-term use
are essential. Late high-grade toxicities have been observed
with other CLL therapies [30]. In this study, no unexpected
AEs were identified after extended follow-up of ibrutinib-
treated patients. Patients continued to experience new AEs
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throughout extended treatment, with some AEs appearing as
late events, such as cataracts, fall, and herpes zoster,
although the impact of aging in this patient population with
extended follow-up cannot be fully accounted for. In the
primary analysis of RESONATE-2 (median follow-up,
18 months), the three most common AEs were diarrhea
(42%), fatigue (30%), and cough (22%) [8], while in the
current analysis at median of 5 years of follow-up (~3.3-
fold longer exposure to ibrutinib) these AEs continue to be
the most common events in 50%, 36%, and 36% of patients,
respectively. Compared with a younger enrolled patient
population treated with ibrutinib plus rituximab for a shorter
median follow-up of 33 months in the phase 3
ECOG1912 study, more ibrutinib-treated patients in
RESONATE-2 (~1.8-fold longer exposure to ibrutinib)
experienced grade ≥3 AEs (83% vs 58%) overall, although
there was a lower frequency of grade ≥3 AEs in the ibrutinib
plus rituximab cohort compared with the FCR cohort in
ECOG1912 (58% vs 72%) [31]. Compared with a similar
patient population in the ALLIANCE study, fewer
ibrutinib-treated patients in RESONATE-2 experienced
grade ≥3 hypertension than ibrutinib-treated patients in
the ALLIANCE study (8% vs 29%), despite the difference
in follow-up (median: 60 months vs 38 months, respec-
tively) [25].
Overall, many AEs decreased over time in this study,
with some exceptions, such as hypertension (the prevalence
of grade ≥3 hypertension remained stable over time). The
incidence of major hemorrhage was generally highest in the
first 2 years of treatment and decreased thereafter. Based on
prior reports, the risk for bleeding with ibrutinib is most
often observed within the first 12 months of treatment and
then decreases over time [27, 32, 33]. Similarly, atrial
fibrillation typically occurs early after ibrutinib initiation
and remains constant or declines over time [7, 34–36]. In
this study after a median follow-up of 5 years, the cumu-
lative rate of major hemorrhage increased from 4% at the
primary analysis to 11%, and for atrial fibrillation increased
from 6% to 16%; however, few patients required dose
reduction or discontinued because of these AEs. Overall,
dose reductions and discontinuations due to AEs were
infrequent and discontinuations due to AEs decreased over
time with continued treatment, with 73% of patients
receiving ibrutinib for >3 years. The ongoing incidence of
new AEs and increasing prevalence of hypertension high-
lights the importance of ongoing follow-up and monitoring
during treatment to maximize optimal management of AEs
with dose modifications (dose holds and reductions) and
thus mitigate the impact of AEs and enable patients to
continue to benefit from ongoing first-line ibrutinib.
As novel agents continue to be developed for CLL, long-
term data are crucial to inform practice. Additional BTK
inhibitors in development for CLL have shown encouraging
efficacy, but results of randomized comparative studies are
not yet available and these agents lack long-term safety and
efficacy data [37, 38]. Here, we demonstrated that with a
median of 5 years of follow-up, over half of patients with
CLL/SLL were able to receive long-term continuous first-
line treatment with single-agent ibrutinib and had sustained
efficacy benefits (70% of ibrutinib-treated patients estimated
progression-free), including—importantly—in patients with
high-risk prognostic features, such as del(11q) or
unmutated IGHV.
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